Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Masitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT known ✓ | P10721 | 13/20 | 1.00 |
| ▸ | PDGFRA known ✓ | P16234 | 4/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 4/20 | 1.00 |
| ▸ | ABL1 | P00519 | 19/20 | 1.00 |
| ▸ | BCR | P11274 | 13/20 | 1.00 |
| ▸ | ABL2 | P42684 | 8/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | FGR | P09769 | 2/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 1.00 |
| ▸ | NQO2 | P16083 | 2/20 | 1.00 |
| ▸ | EPHA8 | P29322 | 2/20 | 1.00 |
| ▸ | FRK | P42685 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Masitinib SCHEMBL29353195 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL717239 | 1.00 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL2297143 | 0.97 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL1096348 | 0.97 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| Masitinib SCHEMBL30024483 | 0.97 | ABL1 (0.94) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL3301373 | 0.95 | ABL1 (0.91) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL16085058 | 0.94 | ABL1 (0.89) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL717173 | 0.94 | ABL1 (0.88) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL17177780 | 0.93 | ABL1 (0.88) | ABL1BCRKITABL2PDGFRA | |
| SCHEMBL26359118 | 0.93 | ABL1 (0.87) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120078718-A | Oral brain-targeted nanoemulsion and preparation method and application thereof | 四川大学 | 2025-06-03 | — | — | CN | claimed |
| CN-119997963-A | Combination therapy of lactobacillus plantarum strains and cancer treatment method using same | 南韩商GI生物群系公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119497716-A | Crystal form of ENPP1 inhibitor | 石药集团中奇制药技术（石家庄）有限公司 | 2025-02-21 | — | — | CN | claimed |
| CN-113286777-B | Compounds, compositions and methods for modulating iron death and treating excitotoxic disorders | 纽约市哥伦比亚大学理事会 | 2024-10-29 | — | — | CN | claimed |
| CN-116270478-B | Oral brain targeting nanoparticle and application thereof | 四川大学 | 2024-08-30 | — | — | CN | claimed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | claimed |
| CN-117677623-A | Compounds, compositions and methods for modulating iron death and treating excitotoxic disorders | 纽约市哥伦比亚大学理事会 | 2024-03-08 | — | — | CN | claimed |
| CN-116270478-A | Oral brain targeting nanoparticle and application thereof | 四川大学 | 2023-06-23 | — | — | CN | claimed |
| WO-2022240260-A1 | COMBINED THERAPY USING ANTI-CD300C ANTIBODY | 주식회사 센트릭스바이오 | 2022-11-17 | — | — | WO | claimed |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-07 | — | — | US | disclosed |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260083767-A1 | SOLID DOSAGE FORM OF A SMALL MOLECULE ANTIVIRAL AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4705284-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-24 | — | — | US | disclosed |
| US-20220160762-A1 | ENGINEERED IMMUNE CELLS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-05-26 | — | — | US | disclosed |
| EP-3999065-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | Pattern Computer, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| CN-114401723-A | Therapeutic compositions and methods for treating cancer | 帕特恩电脑公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3964206-A1 | COMPOUNDS FOR THE TREATMENT OF COVID-19 | Dompe' Farmaceutici S.P.A. (IT) | 2022-03-09 | — | — | EP | disclosed |
| US-11230741-B2 | Methods and systems for determination of an effective therapeutic regimen and drug discovery | DNA-SEQ, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083767-A1 | SOLID DOSAGE FORM OF A SMALL MOLECULE ANTIVIRAL AND USES THEREOF | PRNP, SARS1, TPMT | KIT 610/4885PDGFRA 1632/4885PDGFRB 2119/4885 |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | KIT 4705/4885PDGFRA 2984/4885PDGFRB 1347/4885 |
| US-20260124226-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NSUN2, SARS1, SNRPE | KIT 4274/4885PDGFRA 1617/4885PDGFRB 1895/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | KIT 975/4885PDGFRA 2233/4885PDGFRB 1972/4885 |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | CCRL2, CFB, CCR3 | KIT 4394/4885PDGFRA 2112/4885PDGFRB 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.